Immuno-oncology goes subcutaneous
A pivotal study of Keytruda’s SC formulation is about to read out, but Roche could get to market first.
Asco-GI 2023 – zolbetuximab opens up a stomach cancer niche
Clinical data back Claudin18.2 as a target for treating stomach cancer – but biomarker diagnosis is needed.
A year of two halves for US approvals
FDA green lights picked up in the second half, but for the really impressive number look at year-five sales.
Big caps bounce back for biopharma
Months of share price declines made 2022 a year to forget for many, but large-caps staged a big recovery in the fourth quarter.
Biopharma’s bolt-on bonanza is set to continue
With interest rates rising and developers focusing on favourite therapy areas, should hopes for mega-deals be reined in?
Amgen saves biopharma’s buyout year
December’s $28bn takeout of Horizon bumps 2022’s M&A numbers to respectable levels.
The biggest-selling drugs of 2023
Move over Comirnaty: Keytruda takes top spot as its indications broaden and demand for Covid vaccines recedes.
